Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: December 10, 2007

AMAG Pharmaceuticals, Inc. to Present at the 26th Annual JPMorgan Healthcare Conference

(Nanowerk News) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc. will present an overview of the Company at the 26th Annual JPMorgan Healthcare Conference at 11:00 a.m. PT on Tuesday, January 8, 2008. The conference is being held January 7-10, 2008, at the Westin St. Francis Hotel in San Francisco, CA.
A live webcast of the presentation will be accessible through the Investors section of the company's web site at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. web site until February 8, 2008.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the Company's lead product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients.
Combidex®, the Company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the Company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Source: AMAG Pharmaceuticals, Inc.